ArcelorMittal Attempt to Take Complete Control of Argentinian Steel Subsidiary

ArcelorMittal, the world’s largest steel company, today announces its intention to launch a cash offer to acquire the 34.7% of outstanding shares in Acindar it does not currently own. The Company currently owns a 65.3% stake in Acindar. The offer is designed to help ArcelorMittal strengthen its position in Argentina and reinforce its commitment to enhancing its business in the country.

The transaction is strategically beneficial to Acindar as it will become core to ArcelorMittal´s long products strategy, acting as a platform to grow and seek further opportunities in Latin America.

Commenting, Lakshmi N. Mittal, President and CEO, ArcelorMittal, said:

“ Latin America is a very important steel market with great potential for further growth and one which we have identified as a key region for expansion. This tender offer for Acindar underlines our commitment to the region and demonstrates our desire to strengthen our investment in Argentina. We believe that Acindar will benefit from being a wholly-owned subsidiary of ArcelorMittal and from the benefits of the simplified corporate structure that this transaction brings.”

Commenting, Arturo Acevedo, CEO of Acindar, said:

“Being a member of ArcelorMittal, the world’s leading steel company, brings considerable benefits for Acindar which will be further strengthened by this transaction. For example, Acindar is in the process of completing a USD150m capital programme that will raise capacity to 1.7 million tonnes. This transaction will assist Acindar in furthering investment plans and increasing its presence in the Latin American market.”

As part of its commitment to strengthen Acindar and its position in Argentina, ArcelorMittal is transferring the Acindar shares it currently owns through Arcelor Brasil directly under the parent corporate structure of ArcelorMittal. In connection with such corporate reorganization ArcelorMittal has decided to make an equitable offer to the minority shareholders of Acindar. The successful completion of this Offer will accordingly benefit ArcelorMittal and its shareholders.

ArcelorMittal intends to offer Acindar shareholders AR$5.75 in cash, equivalent to USD1.83, as of October 1, 2007, for each Acindar share they hold, representing a 19.5% premium over Acindar’s closing stock price on October 1, 2007, and a 38.3% premium over Acindar’s average closing stock price over the past six months. The 34.7% stake corresponds to 296,973,709 shares of Acindar as of September 30th, 2007 and represents a potential total transaction value of AR$1,708 million, equivalent to USD542 million as of October 1, 2007. It is intended that the transaction would be funded entirely with cash.

The Offer will be made directly to the shareholders of Acindar by ArcelorMittal’s wholly owned subsidiary ArcelorMittal Spain, and, subject to regulatory approval, ArcelorMittal intends to commence the contemplated Offer no later than 4 months as from today.

The Offer will be conditioned upon, among other things, the tender of a majority of the shares not held by ArcelorMittal and its affiliates and a resulting ownership post transaction by ArcelorMittal of at least 90.0% of the outstanding shares of Acindar.

JP Morgan is acting as exclusive arranger and dealer manager and Bruchou, Fernandez Madero & Lombardi is acting as legal advisor to ArcelorMittal in connection with the Offer.

The authorization to carry out this Offer shall be requested to the Argentine Securities Commission, as per applicable regulations, within the next 10 days, and therefore, such authorization has not been granted yet. Consequently, the information included herein is subject to modification and cannot be deemed as final.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.